CapitalBio Corporation, founded by Dr. Cheng Jing and based in Beijing, China, develops patented, biochip-based analysis products that optimize life sciences research, clinical diagnostics, and drug discovery processes. The company provides clients with infectious disease and cancer gene chip, drug screen, stimulant drug preparation, confocal microarray scanner, data management, oligo library, sample preparation, and other systems. It is known for its LuxScan (TM) and SmartArrayer (TM) products, which are based on technology transferred from Capital Biochip Corporation, AVIVA Biosciences Corporation (San Diego, California), Chipscreen Biosciences Company Limited (Shenzhen, China), and Beijing Wangdong Medical Equipment Company Limited. Beijing Wandong Medical Equipment is listed on the Shanghai Stock Exchange. CapitalBio investors include Tinghua Holdings Company Limited, Huazhong University of Science & Technology HI-Tech Group Company Limited, Beijing Pharmaceutical Group Company Limited, Tianjin Sunco Investment Incorporated, Beijing Union Medical & Pharmaceutical General Corporation, and Four Rings Science & Technology and Development Company. CapitalBio is affiliated with the National Engineering Research Center for Beijing Biochip Technology (NERCBBT), which maintains a 260,000 square foot facility in Beijing. NERCBBT was established in 2000. It conducts biochip, nanotechnology, bioinformatics, and other research. It also operates as a national education and training center. CapitalBio, through its acquisition of Beijing Wangdong Medical Equipment, is focusing on the commercialization of biochip-based analytical and diagnostic instruments.